Raffaele Giusti, European Expert at European Medicines Agency, shared JAMA Oncology’s post on X:
“Buprenorphine is not a first-line mandate in cancer pain. No comparative superiority over full µ-agonists; oncology guidance and WHO/EML keep morphine central. Policy should follow evidence – run pragmatic head-to-head trials now.”
Quoting JAMA Oncology’s post about a recent paper by Amy A. Case et al.:
“Viewpoint: As palliative care clinicians, we urge the adoption of buprenorphine as a first-line opioid for cancer pain due to its effectiveness and safety profile.”
Title: Buprenorphine for Cancer Pain—The Safest Opioid, and Patients With Cancer Cannot Get It
Authors: Amy A. Case, Mellar P. Davis, Marcin Chwistek, Ali J. Zarrabi
More posts featuring Raffaele Giusti.